Preveceutical Medical (PREV-Cse) Further Successful Results from The Sol-Gel Program Final Report
June 15, '20 - NR
Preveceutical Medica is pleased to announce the successful completion of its cannabinoid sol-gel program (the “Sol-gel Program”) with the University of Queensland (“UQ”) and UniQuest Pty Ltd. (“UniQuest).
The final report confirms the successful chemical profiling of the solvent-derived cannabinoid extracts from cannabis plant species, which has provided the Company valuable information for formulation development using cannabinoid sol-gels. This enables PreveCeutical to control the quality of batch-to-batch variations in plant extract chemistries. This will provide optimization of sol-gel formulation strategies. PreveCeutical will now be able to develop and commercialize different combinations of the cannabinoid extracts to be infused into sol-gel formulations for appropriate treatments of different ailments. PreveCeutical’s objectives are to develop, commercialize, and seek other third party clinical-proven formulations to be infused with the sol-gel delivery platform.
The cannabinoid Sol-gel Program for nose-to-brain delivery has been developed to be water-soluble without alcohol or solvent content. The benefits associated with this is that it will be available for neo-natal, seniors, religious, and individual personal choices.
Extraction and chemical fingerprinting of cannabis extracts (news releases on September 4, 2018, and November 5, 2018). Infusion of cannabis extracts, acid and neutral CBD forms (news release November 20, 2018), into wholly water-based sol-gels, using FDA approved excipients (news release July 9, 2019). Effective delivery and sustained retention of the cannabis extract infused sol-gels from the nasal spray applicator to the nasal cavity (news release November 19, 2018). Confirmed safety of the cannabis extract infused sol-gels when applied to freshly explanted human mucosal tissue, with no elevation in clinically accepted biomarkers of acute toxicity (news release on January 8, 2020). Successful completion of its Sol-gel Program (news release on June 3, 2020).
Successful completion of its Sol-gel Program (news release on June 3, 2020).
Mr. Stephen Van Deventer, Chairman and CEO, commented, “We are excited with the research findings and successful in-vitro results from the cannabinoid Sol-gel Program. This will potentially create several therapeutic applications in managing controlled delivery of cannabinoidal combinations in clinical study settings, that would be of great value”.
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences. The Company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer at telephone: +1 604 306 9669
Or Investor Relations ir@preveceutical.com |
